Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D pushing pharmacies to close?

Executive Summary

A survey of 507 community pharmacists revealed that about 33% have considered closing their businesses due to worsening cash flow situations under the Medicare Part D prescription drug benefit, the National Community Pharmacists Association says. Fifty-five percent have had to obtain outside loans or financing to supplement the pharmacy's cash flow because of slow reimbursement, the survey finds. Additionally, 89% of pharmacists say they are currently owed at least $20,000 from prescription drug plans, and 18% say they are owed at least $100,000. Rite Aid and Walgreens have embarked on a letter writing campaign encouraging independent pharmacies to sell their pharmacies rather than continue to face financial difficulties under Part D (1"The Pink Sheet" Aug. 21, 2006, p. 21)...

You may also be interested in...



Chains Seek To Acquire Independent Pharmacies, Citing Part D Environment

Two of the leading nationwide chain drugstores - Rite Aid and Walgreens - have embarked on pharmacy acquisition campaigns in response to opportunities created by Medicare Part D

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.

National Drug Stockpiles Create ‘False Sense Of Security’

The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel